Previous 10 | Next 10 |
home / stock / mvrbf / mvrbf news
Medivir AB ( OTC:MVRBF ): Q4 GAAP EPS of -SEK1.32. Revenue of SEK1.4M (-89.7% Y/Y) Press Release More news on: Medivir AB (publ), Medivir AB ADR, Earnings news and commentary, Tech stocks news, ,
HUDDINGE, Sweden , Feb. 13, 2020 /PRNewswire/ -- October - December Significant events during the quarter Preclinical data showing that in addition to its direct effect on cancer cells, MIV-818 also modulates the ...
STOCKHOLM , Feb. 11, 2020 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) invites investors, analysts and the media to an R&D Day in Stockholm , Monday March 2, 2020 , at 14:00 to 16:30 CET . The presentations will, among other things, address new clinical results from...
STOCKHOLM , Jan. 20, 2020 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announces that the phase II study of MIV-711 in patients with osteoarthritis has been published in the respected journal Annals of Internal Medicine ( DOI: 10.7326/M19-0675). The title of the article is ...
STOCKHOLM , Dec. 18, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the first patient has been enrolled and is being dosed with remetinostat gel 1% in an investigator-initiated phase II clinical study in patients with squamous cell carcinoma (SCC). Th...
Medivir AB ( OTC:MVRBF ): Q3 GAAP EPS of -SEK0.95. More news on: Medivir AB (publ), Medivir AB ADR, Earnings news and commentary, Tech stocks news, , Read more ...
STOCKHOLM , Nov. 18, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) reports today that the ninth and final patient was recruited to the phase Ia study of MIV-818 in patients with advanced liver cancer. Based on data from phase Ia, the initial dose of MIV-818 for the phase...
STOCKHOLM , Oct. 30, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that a poster entitled "MIV-818 stimulates an anti-tumor immune response in vitro and enhances the effects of pembrolizumab" was presented at the AACR-NCI-EORTC conference in Boston . The...
STOCKHOLM , Oct. 10, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the first patient has been enrolled in a phase I study to investigate the safety and tolerability of a combination treatment of birinapant and radiation therapy in patients with recur...
Medivir AB ( OTC:MVRBF ): Q2 GAAP EPS of -SEK0.51. More news on: Medivir AB (publ), Medivir AB ADR, Earnings news and commentary, Tech stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Medivir B Company Name:
MVRBF Stock Symbol:
OTCMKTS Market:
MEDIVIR AB - INTERIM REPORT JANUARY - JUNE 2022 PR Newswire STOCKHOLM , Aug. 19, 2022 /PRNewswire/ -- The clinical development of fostrox remains the focus April - June Financial summary for the quarter Net turnover amoun...
Birinapant clinical study initiated by IGM Biosciences PR Newswire STOCKHOLM , Nov. 4, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR ) today announced that IGM Biosciences, Inc. has initiated its clinical study in solid cancers with birinapant (...
Medivir to present at the ProHearings shared Capital Markets Day PR Newswire STOCKHOLM , Oct. 11, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the ProHearings shared Capital Markets Day, Octo...